uniQure, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $70.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Patrick Trucchio has given his Buy rating due to a combination of factors, primarily the strengthening of uniQure’s gene therapy platform as demonstrated by new Fabry disease data. The latest WORLD 2026 results for AMT-191 show robust, lasting, and dose-related increases in α-Gal A activity, stable disease biomarkers, and the ability for many patients to discontinue enzyme replacement therapy, all of which enhance confidence in the program’s long-term potential.
Trucchio also views the emerging safety profile and clearer dose window as constructive, since observed liver enzyme elevations are manageable and help refine future dosing rather than derail development. In his view, the Fabry data, together with ongoing progress in the CNS pipeline and a solid balance sheet, are not yet near-term regulatory catalysts but do add meaningful longer-term value that is not fully reflected in the current share price, supporting a Buy rating and a $70 target.